ERBB2 and triple-negative breast carcinoma: Of 47 patients with invasive breast cancer, 23 were luminal A (48.9%), 16 were luminal B (34%), 5 were non-luminal HER2 (10.6%) and 3 were triple negative breast cancer (6.4%).